Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation
Peripheral blood used as a source of stem cells for transplantation (PBSCT) is known to exert stronger immune-mediated effects compared with BM (BMT). We decided to retrospectively analyze the impact of stem cell source on the OS of CML patients who relapsed after either matched related donor PBSCT...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2013-06, Vol.48 (6), p.837-842 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 842 |
|---|---|
| container_issue | 6 |
| container_start_page | 837 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 48 |
| creator | Basak, G W de Wreede, L C van Biezen, A Wiktor-Jedrzejczak, W Halaburda, K Schmid, C Schaap, N Dazzi, F von dem Borne, P A Petersen, E Beelen, D Abayomi, A Volin, L Buzyn, A Gurman, G Bunjes, D Guglielmi, C Olavarria, E de Witte, T |
| description | Peripheral blood used as a source of stem cells for transplantation (PBSCT) is known to exert stronger immune-mediated effects compared with BM (BMT). We decided to retrospectively analyze the impact of stem cell source on the OS of CML patients who relapsed after either matched related donor PBSCT (
N
=168) or BMT (
N
=216) and were treated with donor lymphocyte infusions (DLI). Univariate analysis revealed a lower probability of OS after DLI in patients relapsing after PBSCT vs BMT (66% vs 79% at 5 years,
P
=0.013). However, a multivariate Cox analysis did not reveal any significant impact of PBSCT as a risk factor for decreased OS for patients transplanted in first chronic phase (CP1; hazard ratio (HR) 1.036, 95% confidence interval (CI) 0.619–1.734). A statistical interaction term suggested that the impact of stem cell source on OS after DLI was different for those transplanted in advanced phases (negative impact of previous PBSCT—HR 2.176, 95% CI 0.930–5.091). In summary, the stem cell source does not affect the OS of CML patients who underwent PBSCT in CP1, relapsed and were treated with DLI. However, when the patients were transplanted in advanced phases, previous PBSCT seems to negatively affect OS after DLI compared with BMT. |
| doi_str_mv | 10.1038/bmt.2012.234 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1372055852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A334605601</galeid><sourcerecordid>A334605601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c546t-a16870f05c8e2fa264f6bf2452c22a54b1cc1d840e760d507cbd2b06f8b0e10e3</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhiMEoqVw44wsoSIOZPF33GNVPqVKXOAcOc54k-LYwXZU7f_gB-NoF9qiCiEfLHmemXc881bVc4I3BDP1tpvyhmJCN5TxB9Ux4Y2sBZPiYXWMqVQ1Y_LsqHqS0hXGhHMsHldHlJFGCa6Oq5_vgg8Rud00D8HsMqDR2yWNwSdkSyAPgHIEnSfwGQWLzBCDHw2aduDC2CMHy3eYRo0iOD0nKFnOhevRb9EMcZwHiNqhzoXQo1KvCx7QpGMM1yhlmJAB54qC9ml22medi_TT6pHVLsGzw31Sffvw_uvFp_ryy8fPF-eXtRFc5loTqRpssTAKqNVUcis7S7mghlIteEeMIb3iGBqJe4Eb0_W0w9KqDgPBwE6q1_u6cww_Fki5nca0NqQ9hCW1hDUUC6EE_Q9UCoGVwqKgL_9Cr8ISfflIW1qkVDa4Yf-i1lpEMaWaG2qrHbRlNaGMyqzS7TljXGIhMSnU5h6qnL5sxpSJ27G830l4dSthAO3ykIJb1uGnu-CbPWhiSCmCbec4lvXtWoLb1X5tsV-72q8t9iv4i8Onlm6C_g_8228FOD0AOhntbNm7GdMN13Aqz_haqN5zqYT8FuKt6dwn_Avbj_CO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1365183887</pqid></control><display><type>article</type><title>Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Basak, G W ; de Wreede, L C ; van Biezen, A ; Wiktor-Jedrzejczak, W ; Halaburda, K ; Schmid, C ; Schaap, N ; Dazzi, F ; von dem Borne, P A ; Petersen, E ; Beelen, D ; Abayomi, A ; Volin, L ; Buzyn, A ; Gurman, G ; Bunjes, D ; Guglielmi, C ; Olavarria, E ; de Witte, T</creator><creatorcontrib>Basak, G W ; de Wreede, L C ; van Biezen, A ; Wiktor-Jedrzejczak, W ; Halaburda, K ; Schmid, C ; Schaap, N ; Dazzi, F ; von dem Borne, P A ; Petersen, E ; Beelen, D ; Abayomi, A ; Volin, L ; Buzyn, A ; Gurman, G ; Bunjes, D ; Guglielmi, C ; Olavarria, E ; de Witte, T ; Chronic Malignancies Working Party EBMT</creatorcontrib><description>Peripheral blood used as a source of stem cells for transplantation (PBSCT) is known to exert stronger immune-mediated effects compared with BM (BMT). We decided to retrospectively analyze the impact of stem cell source on the OS of CML patients who relapsed after either matched related donor PBSCT (
N
=168) or BMT (
N
=216) and were treated with donor lymphocyte infusions (DLI). Univariate analysis revealed a lower probability of OS after DLI in patients relapsing after PBSCT vs BMT (66% vs 79% at 5 years,
P
=0.013). However, a multivariate Cox analysis did not reveal any significant impact of PBSCT as a risk factor for decreased OS for patients transplanted in first chronic phase (CP1; hazard ratio (HR) 1.036, 95% confidence interval (CI) 0.619–1.734). A statistical interaction term suggested that the impact of stem cell source on OS after DLI was different for those transplanted in advanced phases (negative impact of previous PBSCT—HR 2.176, 95% CI 0.930–5.091). In summary, the stem cell source does not affect the OS of CML patients who underwent PBSCT in CP1, relapsed and were treated with DLI. However, when the patients were transplanted in advanced phases, previous PBSCT seems to negatively affect OS after DLI compared with BMT.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2012.234</identifier><identifier>PMID: 23178548</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/1904 ; 692/699/67/1990/283/1896 ; 692/700/565/251 ; Adult ; Allografts ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood ; Bone marrow ; Bone Marrow Transplantation ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Care and treatment ; Cell Biology ; Chronic myeloid leukemia ; Confidence intervals ; Diseases ; Female ; Follow-Up Studies ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Impact analysis ; Internal Medicine ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - prevention & control ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphocyte Transfusion ; Lymphocytes ; Medical sciences ; Medicine ; Medicine & Public Health ; Myeloid leukemia ; original-article ; Patients ; Peripheral blood ; Peripheral Blood Stem Cell Transplantation ; Public Health ; Recurrence ; Relapse ; Retrospective Studies ; Risk analysis ; Risk factors ; Statistical analysis ; Stem cell transplantation ; Stem Cells ; Tissue Donors ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation</subject><ispartof>Bone marrow transplantation (Basingstoke), 2013-06, Vol.48 (6), p.837-842</ispartof><rights>Macmillan Publishers Limited 2013</rights><rights>2014 INIST-CNRS</rights><rights>COPYRIGHT 2013 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jun 2013</rights><rights>Macmillan Publishers Limited 2013.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c546t-a16870f05c8e2fa264f6bf2452c22a54b1cc1d840e760d507cbd2b06f8b0e10e3</citedby><cites>FETCH-LOGICAL-c546t-a16870f05c8e2fa264f6bf2452c22a54b1cc1d840e760d507cbd2b06f8b0e10e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27426944$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23178548$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Basak, G W</creatorcontrib><creatorcontrib>de Wreede, L C</creatorcontrib><creatorcontrib>van Biezen, A</creatorcontrib><creatorcontrib>Wiktor-Jedrzejczak, W</creatorcontrib><creatorcontrib>Halaburda, K</creatorcontrib><creatorcontrib>Schmid, C</creatorcontrib><creatorcontrib>Schaap, N</creatorcontrib><creatorcontrib>Dazzi, F</creatorcontrib><creatorcontrib>von dem Borne, P A</creatorcontrib><creatorcontrib>Petersen, E</creatorcontrib><creatorcontrib>Beelen, D</creatorcontrib><creatorcontrib>Abayomi, A</creatorcontrib><creatorcontrib>Volin, L</creatorcontrib><creatorcontrib>Buzyn, A</creatorcontrib><creatorcontrib>Gurman, G</creatorcontrib><creatorcontrib>Bunjes, D</creatorcontrib><creatorcontrib>Guglielmi, C</creatorcontrib><creatorcontrib>Olavarria, E</creatorcontrib><creatorcontrib>de Witte, T</creatorcontrib><creatorcontrib>Chronic Malignancies Working Party EBMT</creatorcontrib><title>Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Peripheral blood used as a source of stem cells for transplantation (PBSCT) is known to exert stronger immune-mediated effects compared with BM (BMT). We decided to retrospectively analyze the impact of stem cell source on the OS of CML patients who relapsed after either matched related donor PBSCT (
N
=168) or BMT (
N
=216) and were treated with donor lymphocyte infusions (DLI). Univariate analysis revealed a lower probability of OS after DLI in patients relapsing after PBSCT vs BMT (66% vs 79% at 5 years,
P
=0.013). However, a multivariate Cox analysis did not reveal any significant impact of PBSCT as a risk factor for decreased OS for patients transplanted in first chronic phase (CP1; hazard ratio (HR) 1.036, 95% confidence interval (CI) 0.619–1.734). A statistical interaction term suggested that the impact of stem cell source on OS after DLI was different for those transplanted in advanced phases (negative impact of previous PBSCT—HR 2.176, 95% CI 0.930–5.091). In summary, the stem cell source does not affect the OS of CML patients who underwent PBSCT in CP1, relapsed and were treated with DLI. However, when the patients were transplanted in advanced phases, previous PBSCT seems to negatively affect OS after DLI compared with BMT.</description><subject>631/250/1904</subject><subject>692/699/67/1990/283/1896</subject><subject>692/700/565/251</subject><subject>Adult</subject><subject>Allografts</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Bone marrow</subject><subject>Bone Marrow Transplantation</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Chronic myeloid leukemia</subject><subject>Confidence intervals</subject><subject>Diseases</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Impact analysis</subject><subject>Internal Medicine</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - prevention & control</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphocyte Transfusion</subject><subject>Lymphocytes</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Myeloid leukemia</subject><subject>original-article</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Peripheral Blood Stem Cell Transplantation</subject><subject>Public Health</subject><subject>Recurrence</subject><subject>Relapse</subject><subject>Retrospective Studies</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Statistical analysis</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Tissue Donors</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkk1v1DAQhiMEoqVw44wsoSIOZPF33GNVPqVKXOAcOc54k-LYwXZU7f_gB-NoF9qiCiEfLHmemXc881bVc4I3BDP1tpvyhmJCN5TxB9Ux4Y2sBZPiYXWMqVQ1Y_LsqHqS0hXGhHMsHldHlJFGCa6Oq5_vgg8Rud00D8HsMqDR2yWNwSdkSyAPgHIEnSfwGQWLzBCDHw2aduDC2CMHy3eYRo0iOD0nKFnOhevRb9EMcZwHiNqhzoXQo1KvCx7QpGMM1yhlmJAB54qC9ml22medi_TT6pHVLsGzw31Sffvw_uvFp_ryy8fPF-eXtRFc5loTqRpssTAKqNVUcis7S7mghlIteEeMIb3iGBqJe4Eb0_W0w9KqDgPBwE6q1_u6cww_Fki5nca0NqQ9hCW1hDUUC6EE_Q9UCoGVwqKgL_9Cr8ISfflIW1qkVDa4Yf-i1lpEMaWaG2qrHbRlNaGMyqzS7TljXGIhMSnU5h6qnL5sxpSJ27G830l4dSthAO3ykIJb1uGnu-CbPWhiSCmCbec4lvXtWoLb1X5tsV-72q8t9iv4i8Onlm6C_g_8228FOD0AOhntbNm7GdMN13Aqz_haqN5zqYT8FuKt6dwn_Avbj_CO</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Basak, G W</creator><creator>de Wreede, L C</creator><creator>van Biezen, A</creator><creator>Wiktor-Jedrzejczak, W</creator><creator>Halaburda, K</creator><creator>Schmid, C</creator><creator>Schaap, N</creator><creator>Dazzi, F</creator><creator>von dem Borne, P A</creator><creator>Petersen, E</creator><creator>Beelen, D</creator><creator>Abayomi, A</creator><creator>Volin, L</creator><creator>Buzyn, A</creator><creator>Gurman, G</creator><creator>Bunjes, D</creator><creator>Guglielmi, C</creator><creator>Olavarria, E</creator><creator>de Witte, T</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20130601</creationdate><title>Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation</title><author>Basak, G W ; de Wreede, L C ; van Biezen, A ; Wiktor-Jedrzejczak, W ; Halaburda, K ; Schmid, C ; Schaap, N ; Dazzi, F ; von dem Borne, P A ; Petersen, E ; Beelen, D ; Abayomi, A ; Volin, L ; Buzyn, A ; Gurman, G ; Bunjes, D ; Guglielmi, C ; Olavarria, E ; de Witte, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c546t-a16870f05c8e2fa264f6bf2452c22a54b1cc1d840e760d507cbd2b06f8b0e10e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>631/250/1904</topic><topic>692/699/67/1990/283/1896</topic><topic>692/700/565/251</topic><topic>Adult</topic><topic>Allografts</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Bone marrow</topic><topic>Bone Marrow Transplantation</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Chronic myeloid leukemia</topic><topic>Confidence intervals</topic><topic>Diseases</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Impact analysis</topic><topic>Internal Medicine</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - prevention & control</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphocyte Transfusion</topic><topic>Lymphocytes</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Myeloid leukemia</topic><topic>original-article</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Peripheral Blood Stem Cell Transplantation</topic><topic>Public Health</topic><topic>Recurrence</topic><topic>Relapse</topic><topic>Retrospective Studies</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Statistical analysis</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Tissue Donors</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Basak, G W</creatorcontrib><creatorcontrib>de Wreede, L C</creatorcontrib><creatorcontrib>van Biezen, A</creatorcontrib><creatorcontrib>Wiktor-Jedrzejczak, W</creatorcontrib><creatorcontrib>Halaburda, K</creatorcontrib><creatorcontrib>Schmid, C</creatorcontrib><creatorcontrib>Schaap, N</creatorcontrib><creatorcontrib>Dazzi, F</creatorcontrib><creatorcontrib>von dem Borne, P A</creatorcontrib><creatorcontrib>Petersen, E</creatorcontrib><creatorcontrib>Beelen, D</creatorcontrib><creatorcontrib>Abayomi, A</creatorcontrib><creatorcontrib>Volin, L</creatorcontrib><creatorcontrib>Buzyn, A</creatorcontrib><creatorcontrib>Gurman, G</creatorcontrib><creatorcontrib>Bunjes, D</creatorcontrib><creatorcontrib>Guglielmi, C</creatorcontrib><creatorcontrib>Olavarria, E</creatorcontrib><creatorcontrib>de Witte, T</creatorcontrib><creatorcontrib>Chronic Malignancies Working Party EBMT</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Basak, G W</au><au>de Wreede, L C</au><au>van Biezen, A</au><au>Wiktor-Jedrzejczak, W</au><au>Halaburda, K</au><au>Schmid, C</au><au>Schaap, N</au><au>Dazzi, F</au><au>von dem Borne, P A</au><au>Petersen, E</au><au>Beelen, D</au><au>Abayomi, A</au><au>Volin, L</au><au>Buzyn, A</au><au>Gurman, G</au><au>Bunjes, D</au><au>Guglielmi, C</au><au>Olavarria, E</au><au>de Witte, T</au><aucorp>Chronic Malignancies Working Party EBMT</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>48</volume><issue>6</issue><spage>837</spage><epage>842</epage><pages>837-842</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>Peripheral blood used as a source of stem cells for transplantation (PBSCT) is known to exert stronger immune-mediated effects compared with BM (BMT). We decided to retrospectively analyze the impact of stem cell source on the OS of CML patients who relapsed after either matched related donor PBSCT (
N
=168) or BMT (
N
=216) and were treated with donor lymphocyte infusions (DLI). Univariate analysis revealed a lower probability of OS after DLI in patients relapsing after PBSCT vs BMT (66% vs 79% at 5 years,
P
=0.013). However, a multivariate Cox analysis did not reveal any significant impact of PBSCT as a risk factor for decreased OS for patients transplanted in first chronic phase (CP1; hazard ratio (HR) 1.036, 95% confidence interval (CI) 0.619–1.734). A statistical interaction term suggested that the impact of stem cell source on OS after DLI was different for those transplanted in advanced phases (negative impact of previous PBSCT—HR 2.176, 95% CI 0.930–5.091). In summary, the stem cell source does not affect the OS of CML patients who underwent PBSCT in CP1, relapsed and were treated with DLI. However, when the patients were transplanted in advanced phases, previous PBSCT seems to negatively affect OS after DLI compared with BMT.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>23178548</pmid><doi>10.1038/bmt.2012.234</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2013-06, Vol.48 (6), p.837-842 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1372055852 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | 631/250/1904 692/699/67/1990/283/1896 692/700/565/251 Adult Allografts Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood Bone marrow Bone Marrow Transplantation Bone marrow, stem cells transplantation. Graft versus host reaction Care and treatment Cell Biology Chronic myeloid leukemia Confidence intervals Diseases Female Follow-Up Studies Hematologic and hematopoietic diseases Hematology Humans Impact analysis Internal Medicine Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Leukemia, Myelogenous, Chronic, BCR-ABL Positive - prevention & control Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphocyte Transfusion Lymphocytes Medical sciences Medicine Medicine & Public Health Myeloid leukemia original-article Patients Peripheral blood Peripheral Blood Stem Cell Transplantation Public Health Recurrence Relapse Retrospective Studies Risk analysis Risk factors Statistical analysis Stem cell transplantation Stem Cells Tissue Donors Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation |
| title | Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A36%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Donor%20lymphocyte%20infusions%20for%20the%20treatment%20of%20chronic%20myeloid%20leukemia%20relapse%20following%20peripheral%20blood%20or%20bone%20marrow%20stem%20cell%20transplantation&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Basak,%20G%20W&rft.aucorp=Chronic%20Malignancies%20Working%20Party%20EBMT&rft.date=2013-06-01&rft.volume=48&rft.issue=6&rft.spage=837&rft.epage=842&rft.pages=837-842&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/bmt.2012.234&rft_dat=%3Cgale_proqu%3EA334605601%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1365183887&rft_id=info:pmid/23178548&rft_galeid=A334605601&rfr_iscdi=true |